Why It Matters
Treatment Advocacy Center, a national nonprofit focused on mental health treatment, has terminated its lobbying relationship with Tulipifera Strategies LLC after more than a year of advocacy work, according to a termination filing signed in late August.
The termination comes as Congress continues to grapple with the future of Medicaid's Institutions for Mental Diseases (IMD) exclusion. This decades-old provision bars federal funding for treatment provided in certain inpatient psychiatric facilities.
The engagement represented a modest but consistent investment in federal advocacy work focused exclusively on the IMD Exclusion, found in Section 1905(a) of the Social Security Act.
By The Numbers
Treatment Advocacy Center engaged Tulipifera Strategies in the second quarter of 2025 and disclosed $10,000 per quarter until the recent termination.
Broader Context
The provision generally excludes federal fund participation for treatment provided in inpatient psychiatric facilities.
Congress addressed the exclusion as part of broader legislative efforts in 2025. The One Big Beautiful Bill Act, signed into law on July 4, 2025, did not include a full repeal of the IMD Exclusion, though the exclusion itself remains in statute.
The timing of the termination filing, signed on August 28 comes roughly a year after the legislative effort fell short of the organization's apparent goals. The extended engagement with Tulipifera Strategies through the first quarter of 2026 suggests the organization continued pursuing incremental progress even as the broader legislative landscape proved resistant to major changes.
The Bottom Line
Michael Gray, a Principal at Tulipifera Strategies, served as the primary lobbyist on the Treatment Advocacy Center account.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article